Unknown

Dataset Information

0

A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.


ABSTRACT: To evaluate multiple doses of gabapentin 250 mg on polysomnography (PSG) and participant-reported sleep assessments in a 5-h phase advance insomnia model.Adults reporting occasional disturbed sleep received gabapentin 250 mg (n = 128) or placebo (n = 128). On Days 1 and 28, participants received medication 30 min before bedtime and were in bed from 17:00 to 01:00, ?5 h before their habitual bedtime. Sleep was assessed by PSG, a post sleep questionnaire, and the Karolinska Sleep Diary. Next-day residual effects and tolerability were evaluated. On Days 2-27, participants took medication at home 30 min before their habitual bedtime.Treatment-group demographics were comparable. Gabapentin resulted in significantly less PSG wake after sleep onset (WASO) compared with placebo on Day 1 (primary endpoint, mean: 107.0 versus 149.1 min, p ? 0.001) and Day 28 (113.6 versus 152.3 min, p = 0.002), and significantly greater total sleep time (TST; Day 1: 347.6 versus 283.9 min; Day 28: 335.3 versus 289.1 min) (p ? 0.001). Participant-reported WASO and TST also showed significant treatment effects on both days. Gabapentin was associated with less %stage1 on Day 1, and greater %REM on Day 28, versus placebo. During home use, gabapentin resulted in significantly less participant-reported WASO and higher ratings of sleep quality. Gabapentin was well tolerated (most common adverse events: headache, somnolence) with no evidence of next-day impairment.Gabapentin 250 mg resulted in greater PSG and participant-reported sleep duration following a 5-h phase advance on Day 1 and Day 28 of use without evidence of next-day impairment, and greater sleep duration during at-home use.

SUBMITTER: Furey SA 

PROVIDER: S-EPMC4173088 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4173087 | BioStudies
2013-01-01 | S-EPMC3792393 | BioStudies
2019-01-01 | S-EPMC6970953 | BioStudies
2017-01-01 | S-EPMC5380148 | BioStudies
2019-01-01 | S-EPMC6688709 | BioStudies
2010-01-01 | S-EPMC2819582 | BioStudies
2019-01-01 | S-EPMC6760396 | BioStudies
2015-01-01 | S-EPMC4542146 | BioStudies
2019-01-01 | S-EPMC6594867 | BioStudies
2015-01-01 | S-EPMC5433423 | BioStudies